Stockscreener 앱 받기
1.14
2.56%
-0.03
시장 영업 전:
1.14
Metagenomi Therapeutics Inc 주식(MGX)의 최신 뉴스
Metagenomi Therapeutics (MGX) director awarded 17,400 stock options at $1.23 - Stock Titan
Metagenomi Therapeutics (MGX) director awarded options on 21,000 shares - Stock Titan
Metagenomi Therapeutics (MGX) director receives 21,000-share stock option grant at $1.23 - Stock Titan
Metagenomi (NASDAQ: MGX) director receives 21,000 stock options at $1.23 strike - Stock Titan
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock - Investing.com UK
Metagenomi CEO Jian Irish sells $4,854 in company stock - Investing.com UK
Metagenomi general counsel Wein sells $724 in common stock - Investing.com UK
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock By Investing.com - Investing.com Australia
[Form 4] Metagenomi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Tax-driven sale as Metagenomi (MGX) director Irish reports 3,737 shares sold - Stock Titan
Metagenomi Announces Board Changes and Shareholder Meeting Results - TipRanks
Metagenomi Therapeutics, Inc. Announces Resignation of Brian C. Thomas, Ph.D. as A Member of the Board, Effective as of June 9, 2026 - marketscreener.com
Brian C. Thomas resigns from Metagenomi board effective June 9, 2026 - TradingView
Metagenomi (NASDAQ: MGX) director exits as shareholders back board - Stock Titan
MGX: Directors and auditor were approved, with no stockholder questions or new nominations - TradingView
MGX: Directors elected, auditor ratified, and all proposals approved with no shareholder questions - TradingView
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Metagenomi Therapeutics (MGX) Slides 2.86% as Stock Tests Key Support LevelsSweep Order Flow - newsline.com
MGX Q1 2026 Earnings: Losses Widen Beyond Expectations as Pre-Revenue Biotech Focuses on PipelineEarnings Forecast Report - thelegaladvocate.com
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference - The Manila Times
MGX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEPS Growth Report - The Legal Advocate
MGX Q1 2026 Earnings: Missed Expectations as Pre-Revenue Biotech Advances Gene Editing PipelineEarnings Cycle Outlook - Newser
PRN_FinancialWrapper - FinancialContent
Number of shareholders of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Metagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50 - MSN
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Analysts Have Lowered Expectations For Metagenomi Therapeutics, Inc. (NASDAQ:MGX) After Its Latest Results - simplywall.st
Metagenomi Therapeutics (MGX) reports Q1 loss, misses revenue estimates - MSN
Wells Fargo Maintains Metagenomi Therapeutics(MGX.US) With Buy Rating, Cuts Target Price to $9 - Moomoo
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
MSN Money - MSN
Metagenomi Highlights Q1 Progress on MGX-001 Gene Therapy - TipRanks
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - The Manila Times
Metagenomi Therapeutics: Q1 Earnings Snapshot - kare11.com
Metagenomi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Metagenomi Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Metagenomi (NASDAQ: MGX) details Q1 2026 loss, cash runway and MGX-001 IND plans - Stock Titan
Metagenomi gene edit for hemophilia A targets 2027 human trials - Stock Titan
MGX Stock Price, Quote & Chart | METAGENOMI THERAPEUTICS INC (NASDAQ:MGX) - ChartMill
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
SEC Form DEF 14A filed by Metagenomi Therapeutics Inc. - Quantisnow
[DEF 14A] Metagenomi Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
MGX Price Today: Metagenomi Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Metagenomi Therapeutics (MGX) Stock: Sentiment Analysis (Weakens) 2026-04-22Large Cap Trends - Xã Thanh Hà
MGX Financials: Income Statement, Balance Sheet & Cash Flow | Metagenomi Therapeutics, Inc - Stock Titan
A smaller gene editor cut Atxn2 protein 64% in mice, Metagenomi says - Stock Titan
Metagenomi reports compact gene editing tool in Nature journal - Investing.com
What is the valuation of Metagenomi Therapeutics (MGX) Stock | Price at $1.39, Up 0.72%Stock Surge Alerts - newsline.com
MGX: Metagenomi Therapeutics, Inc.Detailed Earnings Estimates - Zacks Investment Research
Metagenomi Can’t Ax IPO Investor Suit Over Moderna Partnership - Bloomberg Law News
1.27%
1.43%
자본화:
|
볼륨(24시간):